On #WorldCancerResearchDay, we are proud to be evaluating alteration-specific therapies with the mission to discover precise therapies and inspire hope for individuals affected by #cancer. Learn more about us: alterome.com

We’re excited to announce the $35 million extension round of our Series A financing, bringing total funds to nearly $100 million. We will use these proceeds to continue to advance our pipeline of three next-gen #precisiononcology programs. Learn more: bwnews.pr/3h5V1iF

Happy Holidays from Alterome! Thank you to Life Science Cares San Diego for giving us several opportunities in 2022 to give back to our community, including a recent Bike Build for Access Youth Academy & Family Gift-giving for Barrio Logan College Institute 🎓. We're looking forward to continuing the work in 2023!

We’re excited to announce the formation of our Scientific Advisory Board, comprised of four oncology experts who will further strengthen Alterome’s mission to discover precise therapies for individuals affected by cancer. Full press release here: bwnews.pr/3WFT6Bb

On #WorldCancerDay, we’re highlighting the importance of advancing cancer research. At Alterome, we're dedicated to relentlessly pushing the boundaries of cancer treatments to transform the lives of patients, one alteration at a time. Learn more: alterome.com

Our team recently participated in the Padres Pedal the Cause event in support of raising funds for lifesaving #cancerresearch in our hometown of San Diego. We’re proud to support our community in the fight to discover better cancer therapies.

Welcome Andrew Chi, M.D., Ph.D., to Alterome, joining us as CMO. Dr. Chi has 20+ years of experience in oncology research and drug development, and he will be an integral part of our team as we advance our precision oncology programs. Learn more: bit.ly/3E7CsCP

Last week, Alterome teamed up with Life Science Cares San Diego to support our underserved local communities. Together, we packed backpacks for members of Access Youth Academy, filled with the proper learning tools to help better prepare them for the school year ahead. Thank you for having us!

We’re excited to announce that Alterome is on the BioSpace Next Gen “Class of 2024” list! As we continue to advance our pipeline of next-generation precision oncology programs, we’re grateful to be recognized for our efforts. Learn more: bit.ly/3TJPxv6

At Alterome, we take the opportunity to recognize #WorldCancerDay and reflect on our commitment to discovering precise therapies that will transform the lives of cancer patients, one alteration at a time. Learn about who we are and what we do: alterome.com

It’s #EmployeeAppreciationDay, and we are celebrating our amazing Alterhomies! Our team is a diverse group of dedicated individuals whose strong commitment to our mission is our greatest strength. We appreciate you!

We’re excited to announce the closing of our successful $132 million Series B financing that will support the advancement of our two next-generation #precisiononcology programs into clinical development. Full press release: businesswire.com/news/home/2024…

At #AACR24 today, Alterome is presenting preclinical data supporting the development of our AKT1 E17K mutation-selective inhibitor, ALTA-2618. Full press release: bwnews.pr/49rQpsG

We’re thrilled to announce #FDA clearance of #IND application for ALTA2618, the first mutant-selective targeted therapy for AKT1 E17K-mutant cancers. We expect to launch our clinical trial, AKTive001, in Q3 2024.

We’re honored to be chosen as one of San Diego Business Journal’s Best Places to Work in 2024! At Alterome, we know the key to achieving our mission is through the collective success and respect of each team member as we commit to transform the lives of cancer patients.

We are thrilled to announce that Alterome co-founder and CEO, Eric Murphy, has been recognized as one of the Most Exceptional Entrepreneurs of 2024 at Goldman Sachs Builders and Innovators Summit. #GSInnovators More details: bwnews.pr/4h5AdlN

Alterome is presenting new preclinical data supporting the development of our KRAS-selective inhibitor, ALTA3263, at the EORTC-NCI-AACR symposium in Barcelona. #ENA2024 #KRAS Full press release: bwnews.pr/3Ah2xB5

Exciting company news: We announced today that the first patient has been dosed in our AKTive-001 trial of ALTA2618 evaluating patients with AKT1 E17K-mutant advanced solid tumors. Full press release to learn more: bwnews.pr/3A8O1eR

Today, we reflect on the #WorldCancerDay theme “United by Unique,” which places people at the center of their care. At Alterome, we’re committed to precisely targeting validated oncogenic drivers to change the lives of cancer patients, one alteration at a time.